Dr. Dennis Mulac-Hahnen
Food Chemist
Institut für Pharmazeutische Technologie und Biopharmazie
Corrensstr. 48
D - 48149 Münster
Room: C.110.157
Phone: +49 (0)251 - 8339868
Fax: +49 (0)251 - 8339308
E-Mail: mulac.dennis (AT) uni-muenster (DOT) de
Research
Honors
- PHOENIX Pharmazie Wissenschaftspreis – PHOENIX group
Project
- Biokonjugate zur peroralen Anwendung für den Transport von Problemarzneistoffen zur Behandlung des Cholangiozellulären Karzinoms
– BioTraP for CCC ()
Participation in Federally Funded Joint Project: | Federal Ministry of Research, Technology and Space | Project Number: 13N11390
- Biokonjugate zur peroralen Anwendung für den Transport von Problemarzneistoffen zur Behandlung des Cholangiozellulären Karzinoms
– BioTraP for CCC ()
Publications
- Tran, Xenia, Mulac, Dennis, and Langer, Klaus. . “How to deliver an unselective drug selectively: Novel puromycin-loaded albumin nanoparticles for active targeting and their controllable effectiveness.” Journal of Drug Delivery Science and Technology, № 106 doi: 10.1016/j.jddst.2025.106701.
- Kramer, M., Horky, C., Völlmecke, K., van der Linde, M., Mulac, D., Kuckling, D., and Langer, K. . “Smart drug delivery systems: Redox equivalents and pH values as trigger for activation.” contributed to the 5th European Conference on Pharmaceutics, Porto.
- Begasse, T., Eierhoff, T., Mulac, D., and Langer, K. . “Navigating the bloodstream: Insights into protein corona formation and cell interaction of PEGylated nanoparticles.” contributed to the 5th European Conference on Pharmaceutics, Porto.
- Horky, C., Kramer, M., Völlmecke, K., Mulac, D., Kuckling, D., and Langer, K. . “Redox responsive nanoparticles as a promising tool for controlled drug release.” contributed to the 5th European Conference on Pharmaceutics, Porto.
- Lins, Anika, Keuter, Lucas, Mulac, Dennis, Humpf, Hans-Ulrich, and Langer, Klaus. . “Are stabilizers, located on the surface of PLGA nanoparticles, able to modify the protein adsorption pattern?” International Journal of Pharmaceutics, № 674 doi: 10.1016/j.ijpharm.2025.125488.
- zu Vilsendorf, Imke Meyer, Einerhand, Judith, Mulac, Dennis, Langer, Klaus, and Lehr, Matthias. . “1-Benzylindoles as inhibitors of cytosolic phospholipase A2α: synthesis, biological activity, aqueous solubility, and cell permeability.” RSC Medicinal Chemistry 2), № 15 : 641. doi: 10.1039/d3md00590a.
- Tran, Xenia, Mulac, Dennis, and Langer, Klaus. . “Investigating the selectivity of the targeting properties of trastuzumab-bound nanoparticles to HER2/neu positive cells in co-culture.” Journal of Drug Delivery Science and Technology, № 100: 106040. doi: 10.1016/j.jddst.2024.106040.
- Völlmecke, Katharina, Kramer, Maurice, Horky, Corinna, Dueckmann, Oliver, Mulac, Dennis, Langer, Klaus, and Kuckling, Dirk. . “Self-immolative polydisulfides and their use as nanoparticles for drug delivery systems.” RSC Advances 48), № 14 : 35568. doi: 10.1039/d4ra07228f.
- Begasse, T., Eierhoff, T., Mulac, D., and Langer, K. . “In vitro testing of human serum albumin nanoparticles for aortic diseases.” contributed to the 14th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Wien.
- Kramer, M., Völlmecke, K., Mulac, D., Kuckling, D., and Langer, K. . “Preparation of stimuli responsive nanoparticles: Study of stability and decomposition under physiological or pathological conditions.” contributed to the 14th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Wien.
- Laabs, M., Mulac, D., Wünsch, A., and Langer, K. . “Natural or synthetic? Investigation of different phospholipids as coating material for LNPs.” contributed to the 14th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Wien.
- Lins, A., Keuter, L., Mulac, D., Humpf, H.-U., and Langer, K. . “Are stabilizers, located at the surface of PLGA nanoparticles, able to modify the protein adsorption pattern?” contributed to the 14th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Wien.
- Tran, X., Mulac, D., and Langer, K. . “Investigating target selectivity of trastuzumab-bound nanoparticles in co-culture and spheroid cell models.” contributed to the 14th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Wien.
- Kramer, M., Völlmecke, K., Mulac, D., Kuckling, D., and Langer, K. . “Advances in smart drug delivery systems for potential targeted cancer therapy.” contributed to the DPhG Annual Meeting (2024), Münster.
- Horky, C., Kramer, M., Völlmecke, K., Mulac, D., Kuckling, D., and Langer, K. . “Biocompatibility and stimuli-responsive properties of GSH-sensitive nanoparticles.” contributed to the DPhG Annual Meeting (2024), Münster.
- Laabs, M., Mulac, D., and Langer, K. . “Towards better brain drug delivery: The potential of ApoE-functionalized lipid nanoparticles.” contributed to the DPhG Annual Meeting (2024), Münster.
- Lins, A., Keuter, L., Fortmann, M., Mulac, D., Humpf, H.-U., and Langer, K. . “Impact of the protein corona on nanoparticle uptake by macrophages.” contributed to the DPhG Annual Meeting (2024), Münster.
- Tran, X., Mulac, D., and Langer, K. . “Active targeting properties of trastuzumab-bound nanoparticles to HER2/neu-positive cells - now in 3D.” contributed to the DPhG Annual Meeting (2024), Münster.
- Subeska, A, Voundi, ME, Hanekamp, W, Mulac, D, Langer, K, and Lehr, M. . “Synthesis, activity, metabolic stability and cell permeability of new cytosolic phospholipase A2α inhibitors with 1-indolyl-3-phenoxypropan-2-one structure.” Bioorganic and Medicinal Chemistry Letters, № 92: 129374–129374. doi: 10.1016/j.bmcl.2023.129374.
- Adick, A., Hoheisel, W., Schneid, S., Mulac, D., Azhdari, S., and Langer, K. . “Challenges of nanoparticle albumin bound (nab™) technology: Comparative study of Abraxane® with a newly developed albumin-stabilized itraconazole nanosuspension.” European journal of pharmaceutics and biopharmaceutics, № 193: 129–143. doi: 10.1016/j.ejpb.2023.10.022.
- Hester, S., B., Ferenz K., Adick, A., Kakalias, C., Mulac, D., Azhdari, S., and Langer, K. . “Triglyceride-filled albumin-based nanocapsules: A promising new system to avoid discarding poorly water-soluble drug candidates.” International Journal of Pharmaceutics, № 646 doi: 10.1016/j.ijpharm.2023.123454.
- Laabs, M., Mulac, D., Wünsch, A., and Langer, K. . “New lipid-polymer hybrid nanoparticles loaded with flurbiprofenaxetil and coated with apolipoprotein E – A game changer in Alzheimer´s treatment?” contribution to the 4th European Conference on Pharmaceutics, Marseille
- Prell, K., Mulac, D., and Langer, K. . “Ion pairing approach to influence release kinetics of loperamide loaded polymeric nanoparticles and investigation of their behavior at the blood brain barrier.” contribution to the 4th European Conference on Pharmaceutics, Marseille
- Hester, S., Ferenz, K.B., Mulac, D., Kakalias, C., and Langer, K. . “Triglyceride-filled albumin nanocapsules: A new possibility to formulate poorly water-soluble drug candidates.” contribution to the NRW Nanokonferenz, Dortmund
- Laabs, M., Mulac, D., Wünsch, A., and Langer, K. . “Lipoprotein imitating nanoparticles targeting LRP1 – A promising pathway to cross the blood-brain barrier?” contribution to the 22. Barriere- und Transporter-Days, Bad Herrenalb
- Adick, A., Hoheisel, W., Schneid, S., Mulac, D., and Langer, K. . “The nanoparticle albumin bound technology: Formulation of poorly water-soluble drugs for intravenous use.” contribution to the DPhG Annual Meeting, Tübingen
- Kramer, M., Völlmecke, K., Mulac, D., Kuckling, D., and Langer, K. . “Preparation of stimulus responsive nanoparticles: A comparative study of lab techniques and microfluidics.” contribution to the DPhG Annual Meeting, Tübingen
- Laabs, M., Mulac, D., Wünsch, A., and Langer, K. . “Nature as a model: Using phospholipids as coating material for lipid nanoparticles to imitate natural lipoproteins.” contribution to the DPhG Annual Meeting, Tübingen
- Lins, A., Keuter, L., Mulac, D., Humpf, H.-U., and Langer, K. . “Role of stabilizers in protein adsorption patterns of PLGA nanoparticles.” contribution to the DPhG Annual Meeting, Tübingen
- Tran, X., Mulac, D., and Langer, K. . “More advanced cell culture models to investigate the selective targeting of trastuzumab-bound nanoparticles to HER2/neu-positive cells.” contribution to the DPhG Annual Meeting, Tübingen
- Feldmann, Anja, Nitschke, Yvonne, Linss, Franziska, Mulac, Dennis, Stuecker, Sina, Bertrand, Jessica, Buers, Insa, Langer, Klaus, and Rutsch, Frank. . “Improved Reversion of Calcifications in Porcine Aortic Heart Valves Using Elastin-Targeted Nanoparticles.” International Journal of Molecular Sciences 22), № 24 doi: 10.3390/ijms242216471.
- Subeska, A, Althaus, J, Hake, T, Hanekamp, W, Bettenworth, D, Mulac, D, Langer, K, and Lehr, M. . “Synthesis and pharmacokinetic properties of novel cPLA2α inhibitors with 1-(carboxyalkylpyrrolyl)-3-aryloxypropan-2-one structure.” Bioorganic & Medicinal Chemistry, № 77: 117110–117110. doi: 10.1016/j.bmc.2022.117110.
- Barth, C., Spreen, H., Mulac, D., Keuter, L., Behrens, M., Humpf, H.-U., and Langer, K. . “Spacer length and serum protein adsorption affect active targeting of trastuzumab-modified nanoparticles.” Biomaterials and Biosystems, № 5: 100032. doi: 10.1016/j.bbiosy.2021.100032.
- Barth, M., Rudolph, S., Kampschulze, J., Meyer zu Vilsendorf, I., Hanekamp, W., Mulac, D., Langer, K., and Lehr, M. . “Hexafluoroisopropyl carbamates as selective MAGL and dual MAGL/FAAH inhibitors: Biochemical and physicochemical properties.” ChemMedChem, № 17: e2021007. doi: 10.1002/cmdc.202100757.
- Linß, F., Mulac, D., and Langer, K. . “Thiol groups on nanoparticle surfaces promote unspecific cell interaction in targeting studies.” contribution to the 13th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Rotterdam
- Prell, K., Mulac, D., and Langer, K. . “Collagen gels as a support for cell barriers - Investigation of nanoparticle permeation.” contribution to the 13th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Rotterdam
- Spreen, H., Mulac, D., and Langer, K. . “Characterization of nanoparticle-bound trastuzumab adsorption behavior and its cellular interaction.” contribution to the 13th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Rotterdam
- Adick, A., Hoheisel, W., Schneid, S., Mulac, D., Herrmann, F., and Langer, K. . “A closer look at nab™ technology: Systematic characterization of Abraxane®.” contribution to the DPhG Annual Meeting, Marburg
- Laabs, M., Mulac, D., Langer, K., and Wünsch, A. . “Different strategies to formulate flurbiprofen in PEGylated lipid-polymer hybrid nanoparticles carrying it across the blood-brain barrier.” contribution to the DPhG Annual Meeting, Marburg
- Linß, F., Mulac, D., Riehemann, K., and Langer, K. . “Achieving specific vascular targeting of antibody-linked albumin nanoparticles in a pulsatile shear force model.” contribution to the DPhG Annual Meeting, 2022
- Prell, K., Mulac, D., and Langer, K. . “Collagen gels as a support for cell barriers - Investigation of nanoparticle permeation.” contribution to the DPhG Annual Meeting, Marburg
- Tran, X., Mulac, D., and Langer, K. . “Selective targeting of Trastuzumab-bound nanoparticles to HER2/neu-positive SK-Br-3 cells in the presence of non-target MCF-7 cells.” contribution to the DPhG Annual Meeting, Marburg
- Wünsch, A., Mulac, D., and Langer, K. . “Lecithin coating as universal stabilization and functionalization strategy for nanosized drug carriers to overcome the blood-brain barrier.” Int. J. Pharm., № 593: 120146.
- Schoppa, T., Mulac, D., Rust, T., Jung, D., Kuckling, D., and Langer, K. . “New light-responsive polymeric nanoparticles as an on demand drug releasing system.” contribution to the DPhG Annual Meeting, Leipzig online
- Wünsch, A., Mulac, D., and Langer, K. . “Nanoparticles inspired by lipoproteins: A lecithin stabilized and ApoE functionalized carrier system to overcome the blood-brain barrier.” contribution to the DPhG Annual Meeting, Leipzig online
- Wünsch, A., Mulac, D., and Langer, K. . “ApoE-modified Lipid Nanoparticles Enclosing Different Core Variations to Overcome the Blood-Brain Barrier.” contribution to the CRS Virtual Annual Meeting, online
- Schoppa, T., Jung, D., Rust, T., Mulac, D., Kuckling, D., and Langer, K. . “Light-responsive nanoparticles based on a novel nitropiperonal derived polyester as drug delivery systems for photosensitizers in PDT.” Int. J. Pharm., № 597: 120326.
- Spreen, H., Behrens, M., Mulac, D., Humpf, H., and Langer, K. . “Identification of main influencing factors on the protein corona composition of PLGA and PLA nanoparticles.” European journal of pharmaceutics and biopharmaceutics, № 163: 212–222.
- Wünsch, A., Mulac, D., and Langer, K. . “Lipoprotein imitating nanoparticles: Lecithin coating binds ApoE and mediates non-lysosomal uptake leading to transcytosis over the blood-brain barrier.” Int. J. Pharm., № 589: 119821.
- Keuth, J., Nitschke, Y., Mulac, D., Riehemann, K., Rutsch, F., and Langer, K. . “Reversion of arterial calcification by elastin-targeted DTPA-HSA nanoparticles.” Eur. J. Pharm. Biopharm., № 150: 108–119.
- Barth, C., Mulac, D., and Langer, K. . “Influence of PEG spacer selection on active targeting of trastuzumab-modified nanoparticles.” contribution to the DPhG Annual Meeting, Heidelberg, Germany
- Alberding, G., Mulac, D., and Langer, K. . “Surface modification of PLGA nanoparticles with cysteine for oral drug delivery.” contribution to the DPhG Annual Meeting, Heidelberg, Germany
- Wünsch, A., Mulac, D., and Langer, K. . “Lipoprotein mimicking nanoparticles as colloidal drug delivery system.” contribution to the DPhG Annual Meeting, Heidelberg, Germany
- Wünsch, A., Mulac, D., and Langer, K. . “Imitating lipoproteins as drug delivery system - Apolipoprotein E-modified lipid nanoparticles.” contribution to the 21. Bad Herrenalber Transporter-Tage, Bad Herrenalb, Germany
- Backhaus, S., Mulac, D., and Langer, K. . “Are PLGA-based glutathione-modified nanoparticles sufficient to cross the blood-brain barrier?” contribution to the 21. Bad Herrenalber Transporter-Tage, Bad Herrenalb, Germany
- Alberding, G., Mulac, D., and Langer, K. . “PLGA nanoparticles for oral drug delivery: Influence of polymer end groups and particle size on permeability in the Caco-2 model.” contribution to the 21. Bad Herrenalber Transporter-Tage, Bad Herrenalb, Germany
- Backhaus, S., Mulac, D., and Langer, K. . “Preparation and characterization of penetratin-modified PLGA nanoparticles for endothelial cellular uptake.” contribution to the 3rd European Conference on Pharmaceutics – Bringing science into pharmaceutical practice, Bologna, Italy
- Pieper, S., Onafuye, H., Mulac, D., Cinatl, J., Wass, M.N.Michaelis M., and Langer, K. . “Incorporation of doxorubicin in different polymer nanoparticles and their anti-cancer activity.” Beilstein J. Nanotechnol., № 10: 2062–2072.
- Onafuye, H., Pieper, S., Mulac, D., Cinatl, jr. J., Wass, M.N., Langer, K., and Michaelis, M. . “Doxorubicin-loaded human serum albumin nanoparticles overcome transporter-mediated drug resistance.” Beilstein J. Nanotechnol., № 10: 1707–1715.
- Sun, J., Jung, D., Schoppa, T., Anderski, J., Picker, M.-T., Ren, Y., Mulac, D., Stein, N., Langer, K., and Kuckling, D. . “Light-responsive serinol-based poylcarbonate and polyester as degradable scaffolds.” ACS Applied Bio Materials, № 2: 3038–3051.
- Partikel, K., Korte, R., Stein, N.C., Mulac, D., Herrmann, F.C., Humpf, H.-U., and Langer, K. . “Effect of nanoparticle size and PEGylation on the protein corona of PLGA nanoparticles.” Eur. J. Pharm. Biopharm., № 2019: 70–80.
- Mahlert, L., Anderski, J., Schoppa, T., Mulac, D., Sun, J., Kuckling, D., and Langer, K. . “In vitro evaluation of innovative light-responsive nanoparticles for controlled drug release in intestinal PDT.” Int. J. Pharm., № 565: 199–208.
- Partikel, K., Korte, R., Mulac, D., Humpf, H.-U., and Langer, K. . “Serum type and concentration both affecting the protein corona composition of PLGA nanoparticles.” Beilstein J. Nanotechnol., № 10: 1002–1015.
- Mahlert, L., Anderski, J., Mulac, D., and Langer, K. . “The impact of gastrointestinal mucus – new in vitro evaluation of promising mucus-penetrating PLGA-NP for photodynamic therapy in treatment of intestinal cancer.” Eur. J. Pharm. Sci., № 133: 28–39.
- Anderski, J., Mahlert, L., Sun, J., Birnbaum, W., Mulac, D., Schreiber, S., Herrmann, F., Kuckling, D., and Langer, K. . “Light-responsive nanoparticles based on new polycarbonates as innovative drug delivery systems for photosensitizers in PDT.” International Journal of Pharmaceutics, № 557: 182–191.
- Schultheis, J, Beckmann, D, Mulac, D, Müller, L, Esselen, M, and Düfer, M. . “Nrf2 activation protects mouse beta cells from glucolipotoxicity by restoring mitochondrial function and physiological redox balance.” Oxidative medicine and cellular longevity, № 2019 doi: 10.1155/2019/7518510.
- Mahlert, L., Anderski, J., Mulac, D., and Langer, K. . “Overcoming the mucus barrier - in vitro evaluation of mucus permeating nanoparticles for PDT.” contribution to the 11th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Granada, Spanien
- Anderski, J., Mahlert, L., Mulac, D., Sun, J., Birnbaum, W., Kuckling, D., and Langer, K. . “Light-sensitive nanoparticles as innovative drug delivery systems for a controlled drug release.” contribution to the 11th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Granada, Spanien
- Franz, J., Grünebaum, J., Schäfer, M., Mulac, D., Rehfeldt, F., Langer, K., Kramer, A., and Riethmüller, C. . “Rhombic organization of microvilli domains found in a cell model of the human intestine.” PloS one 1), № 13 doi: 10.1371/journal.pone.0189970.
- Gossmann, R., Spek, S., Langer, K., and Mulac, D. . “Didodecyldimethylammonium bromide (DMAB) stabilized poly(lactic-co-glycolic acid) (PLGA) nanoparticles: Uptake and cytotoxic potential in Caco-2 cells.” Journal of Drug Delivery Science and Technology null), № 43 : 430–438. doi: 10.1016/j.jddst.2017.11.002.
- Raudszus, B., Mulac, D., and Langer, K. . “A new preparation strategy for surface modified PLA nanoparticles to enhance uptake by endothelial cells.” International Journal of Pharmaceutics 1), № 536 : 211–221. doi: 10.1016/j.ijpharm.2017.11.047.
- Wünsch, A., Mulac, D., and Langer, K. . “New lipid nanoparticle system based on lipoproteins: Cholesteryl oleate as solid core with different coatings.” contribution to the NRW Nano-Conference, Dortmund, Deutschland
- Stein, N.C., Mulac, D., Hermann, F.C., and Langer, K. . “Preparation and characterization of protein-stabilized mTHPC nanosuspensions.” contribution to the 8th NRW Nano-Conference, Dortmund, Deutschland
- Partikel, K., Mulac, D., and Langer, K. . “The time-dependent nanoparticle-protein corona.” contribution to the 8th NRW Nano-Conference, Dortmund, Deutschland
- Neufeld, N., Mulac, D., and Langer, K. . “Genipin crosslinked HSA nanoparticles for gene therapy: Impact of the crosslinker on transfection efficiency.” contribution to the 8th NRW Nano-Conference, Dortmund, Deutschland
- Keuth, J., Nitschke, Y., Mulac, D., Riehemann, K., Rutsch, F., and Langer, K. . “Reversion of arterial calcification by elastin targeted nanoparticles.” contribution to the 8th NRW Nano-Conference, Dortmund, Deutschland
- Backhaus, S., Mulac, D., and Langer, K. . “Improved cellular uptake of different polysorbate 80-coated PLGA nanoparticles.” contribution to the 8th NRW Nano-Conference, Dortmund, Deutschland
- Anderski, J., Mahlert, L., Mulac, D., and Langer, K. . “Promising nanoparticulate drug delivery systems based on light-cleavable polymers.” contribution to the 8th NRW Nano-Conference, Dortmund, Deutschland
- Alberding, G., Mulac, D., and Langer, K. . “PLGA nanoparticles for oral drug delivery: Know your basics to overcome the hurdles.” contribution to the 8th NRW Nano-Conference, Dortmund, Deutschland
- Wünsch, A., Mulac, D., and Langer, K. . “Formation of colloidal particles by dialysis of mixed albumin solution with lecithin emulsion: Incompatibility or chance for a new lipid-based drug delivery system?” contribution to the DPhG Annual Meeting 2018, Hamburg, Deutschland
- Stein, N.C., Mulac, D., Herrmann, F.C., and Langer, K. . “Nanoparticle albumin-bound technology – Drug properties as a crucial aspect for an application.” contribution to the DPhG Annual Meeting 2018, Hamburg, Deutschland
- Partikel, K., Mulac, D., and Langer, K. . “Compositional evolution of the nanoparticle-protein corona with increasing concentration of human serum.” contribution to the 11th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Granada, Spanien
- Sun, J., Birnbaum, W., Anderski, J., Picker, M.-T., Mulac, D., Langer, K., and Kuckling, D. . “Use of light-degradable aliphatic polycarbonate nanoparticles as drug carrier for photosensitizer.” Biomacromolecules, № 19: 4677–4690.
- Anderski, J., Mahlert, L., Mulac, D., and Langer, K. . “Mucus-penetrating nanoparticles: Promising drug delivery systems for the photodynamic therapy of intestinal cancer.” European journal of pharmaceutics and biopharmaceutics, № 129: 1–9.
- Mesken, J., Iltsche, A., Mulac, D., and Langer, K. . “Modifying plasmid-loaded HSA-nanoparticles with cell penetrating peptides −cellular uptake and enhanced gene delivery.” International Journal of Pharmaceutics, № 522: 198–209. doi: 10.1016/j.ijpharm.2017.03.006.
- Anderski, J., Mahlert, L., Mulac, D., and Langer, K. . “Photosensitizer-loaded nanoparticles: Promising drug delivery systems for photodynamic therapy of intestinal cancer?” contribution to the DPhG Annual Meeting, Saarbrücken, Germany
- Keuth, J., Mulac, D., and Langer, K. . “Challenges in development of EDTA-nanoparticles for therapy of calcification disorders.” contribution to the DPhG Annual Meeting, Saarbrücken, Germany
- Neufeld, N., Mulac, D., and Langer, K. . “Genipin as a bioalternative crosslinker for the stabilization of HSA nanoparticles.” contribution to the DPhG Annual Meeting, Saarbrücken, Germany
- Partikel, K., Korte, R., Hoevelmann, Y., Mulac, D., and Langer, K. . “Effect of different serum types on the formation of the nanoparticle-protein corona.” contribution to the DPhG Annual Meeting, Saarbrücken, Germany
- Backhaus, S., Mulac, D., and Langer, K. . “Different strategies for the formation of blood-brain barrier crossing PLGA nanoparticles.” contribution to the DPhG Annual Meeting, Saarbrücken, Germany
- Lappe, S., Mulac, D., and Langer, K. . “Polymeric nanoparticles – Influence of the glass transition temperature on drug release.” International Journal of Pharmaceutics null), № 517 : 338–347. doi: 10.1016/j.ijpharm.2016.12.025.
- Mesken, J., Iltzsche, A., Mulac, D., and Langer, K. . “EB1 modified HSA nanoparticles as non-viral delivery vectors-Influence of peptide concentration on cell uptake.” in Vol. 4 Elsevier. doi: 10.1016/j.matpr.2017.09.183.
- Raudszus, B., Partikel, K., Mulac, D., and Langer, K. . “Characterisation and cellular uptake of polysorbate 80-coated PLA nanoparticles.” in Vol. 4 Elsevier. doi: 10.1016/j.matpr.2017.09.186.
- Raudszus, B., Partikel, K., Mulac, D., and Langer, K. . “Characterization and cellular uptake of polysorbate 80-coated PLA nanoparticles.” contribution to the 7th NRW Nano-Conference, Münster, Germany
- Partikel, K, Korte, R, Mulac, D, and Langer, K. . “Effect of nanoparticle size on the protein corona: A comparison between 100 and 200 nm PLGA nanoparticles.” contribution to the 7th NRW Nano-Conference, Münster, Germany
- Mesken, J, Mulac, D, and Langer, K. . “Cell penetrating peptides as targeting ligands for nanoparticle based gene therapy – Influence on cellular uptake and transfection efficiency.” contribution to the 7th NRW Nano-Conference, Münster, Germany
- Anderski, J., Mahlert, L., Mulac, D., and Langer, K. . “PLGA-based nanoparticles for oral application of photosensitizers as photodynamic therapy to treat gastrointestinal cancer.” contribution to the 7th NRW Nano-Conference, Münster, Germany
- Niehoff, A., Grünebaum, J., Moosmann, A., Mulac, D., Söbbing, J., Niehaus, R., Buchholz, R., Kröger, S., Wiehe, A., Wagner, S., Sperling, M., von Briesen, H., Langer, K., and Karst, U. . “Quantitative bioimaging of platinum group elements in tumor spheroids.” Analytica Chimica Acta null), № 938 : 106–113. doi: 10.1016/j.aca.2016.07.021.
- Mesken, J., Mulac, D., and Langer, K. . “Non-viral gene therapy: Successful uptake and transfection efficiency by plasmid-loaded protein-nanoparticles modified with cell penetrating peptides.” contribution to the PBP World Meeting, Glasgow, UK
- Gossmann, R., Hummel, M., Mulac, D., Brockmeyer, J., and Langer, K. . “Cationic nanoparticles. An analytical approach to biological relevance.” contribution to the 1st European Conference on Pharmaceutics – Drug Delivery, Reims, France
- Grünebaum, J., Söbbing, J., Mulac, D., and Langer, K. . “Nanoparticulate carriers for photodynamic therapy of cholangiocarcinoma: In vitro comparison of various polymer-based nanoparticles.” International Journal of Pharmaceutics 2), № 496 : 942–952. doi: 10.1016/j.ijpharm.2015.10.023.
- Gossmann, R., Langer, K., and Mulac, D. . “New perspective in the formulation and characterization of didodecyldimethylammonium bromide (DMAB) stabilized poly(lactic-co-glycolic acid) (PLGA) nanoparticles.” PloS one 7), № 10 doi: 10.1371/journal.pone.0127532.
- Gossmann, R., Fahrländer, E., Hummel, M., Mulac, D., Brockmeyer, J., and Langer, K. . “Comparative examination of adsorption of serum proteins on HSA- and PLGA-based nanoparticles using SDS-PAGE and LC-MS.” European journal of pharmaceutics and biopharmaceutics, № 93: 80–87. doi: 10.1016/j.ejpb.2015.03.021.
- Gonnisen, D, Mulac, D, Söbbing, J, Grünebaum, J, Fuchs, H, Langer, K, and Riehemann, K. . “Effects of PLGA nanoparticles on macrophages and cholangiocellular cancer cells.” contribution to the Nanobio europe 2014, Münster
- Söbbing, J, Grünebaum, J, Mulac, D, and Langer, K. . “Are polymeric nanoparticles able to cross the gastrointestinal barrier?” contribution to the DPhG Jahrestagung, Frankfurt
- Gossmann, R, Mulac, D, Hummel, M, Brockmeyer, J, and Langer, K. . “Cationic nanoparticles as promsing drug delivery system? In detail characterization of surface properties.” contribution to the DPhG Jahrestagung, Frankfurt
- Wessels, L, Tacke, S, Mulac, D, and Langer, K. . “Nanocapsules – Is the preparation of core-shell structured nanosystems that simple?” contribution to the DPhG Jahrestagung, Frankfurt
- Grünebaum, J, Söbbing, J, Mulac, D, and Langer, K. . “Improved photocytotoxicity in cholangiocellular cell lines with mTHPP-loaded PLGA nanoparticles.” contribution to the PBP World Meeting, Lissabon
- Gossmann, R, Mulac, D, and Langer, K. . “New perspective in the formulation and characterization of DMAB-stabilized PLGA nanoparticles.” contribution to the PBP World Meeting, Lissabon
- Söbbing, J, Mulac, D, Wieland, G, Wiehe, A, and Langer, K. . “Preparation and physic-chemical evaluation of PLGA nanoparticles for photodynamic tumor therapy.” contribution to the PBP World Meeting, Lissabon
- Mulac, D, Fahrländer, E, Gossmann, R, and Langer, K. . “Comparative examination of adsorption of serum proteins on HSA and PLGA based nanoparticles.” contribution to the PBP World Meeting, Lissabon
- Niehoff, A.-C., Moosmann, A., Söbbing, J., Wiehe, A., Mulac, D., Wehe, C.A., Reifschneider, O., Blaske, F., Wagner, S., Sperling, M., von Briesen, H., Langer, K., and Karst, U. . “A palladium label to monitor nanoparticle-assisted drug delivery of a photosensitizer into tumor spheroids by elemental bioimaging.” Metallomics 1), № 6 : 77–81. doi: 10.1039/c3mt00223c.
- Engel, A., Ploger, M., Mulac, D., and Langer, K. . “Asymmetric flow field-flow fractionation (AF4) for the quantification of nanoparticle release from tablets during dissolution testing.” International Journal of Pharmaceutics 1), № 461 : 137–144. doi: 10.1016/j.ijpharm.2013.11.044.
- Mulac, D, Lepski, S, Ebert, F, Schwerdtle, T, and Humpf, HU. . “Cytotoxicity and fluorescence visualization of ergot alkaloids in human cell lines.” Journal of Agricultural and Food Chemistry 2), № 61 : 462–71. doi: 10.1021/jf304569q.
- Söbbing, J, Grünebaum, J, Mulac, D, and Langer, K. . “Preparation and biological evaluation of mTHPP-loaded PLGA nanoparticles for photodynamic tumor therapy.” contribution to the DPhG Jahrestagung, Freiburg
- Grünebaum, J, Söbbing, J, Engel, A, Mulac, D, and Langer, K. . “Methodische Voraussetzung zur Untersuchung der Permeabilität von Nanopartikeln am Caco-2 Modell.” contribution to the Transportertage Bad Herrenalb, Bad Herrenalb
- Mulac, D, Hüwel, S, Galla, HJ, and Humpf, HU. . “Permeability of ergot alkaloids across the blood-brain barrier in vitro and influence on the barrier integrity.” Molecular Nutrition and Food Research 3), № 56 : 475–85. doi: 10.1002/mnfr.201100431.
- Mulac, D, Grote, AK, Kleigrewe, K, and Humpf, HU. . “Investigation of the metabolism of ergot alkaloids in cell culture by fourier transformation mass spectrometry.” Journal of Agricultural and Food Chemistry 14), № 59 : 7798–807. doi: 10.1021/jf2012024.
- Mulac, D, Grote, AK, Kleigrewe, K, and Humpf, HU. . “Uptake and Metabolism of Ergot Alkaloids in Human Cells.” contribution to the Mykotoxinworkshop, Freising
- Mulac, D, Hüwel, S, Galla, HJ, and Humpf, HU. . “Einfluss von Mutterkornalkaloiden auf die Blut-Hirn-Schranke im in vitro Modellsystem.” contribution to the Treffen der Blut-Hirn-Schranke Experten und Caco-2 Anwender, Bad Herrenalb
- Mulac, D., Königs, M., Schwerdt, G., Gekle, M., and Humpf, H. . “Safety Assessment of Botanicals and Botanical Preparations Used as Ingredients in Food Supplements: Testing an European Food Safety Authority-Tiered ApproachRisk Assessment of T-2 and HT-2 Toxin Using Human Cells in Primary Culture.” in Risk Assessment of Phytochemicals in Food: Novel Approaches, Vol. null , edited by Wiley-Blackwell. Wiley-Blackwell. doi: 10.1002/9783527634705.ch4.
- Mulac, D, and Humpf, HU. . “Cytotoxic effects of ergot alkaloids on human primary cells.” contribution to the Single Cell and Molecule Analysis, Münster
- Mulac, D, Königs, M, Schwerdt, G, Gekle, M, and Humpf, HU. . “Risk assessmentof T-2 and HT-2 toxin using human cells in primary culture.” contribution to the SKLM, Kaiserslautern
- A, Fraske, H, Harrer, F, Hübner, M, Königs, D, Mulac, Humpf, and HU. . “Large-scale Isolation and Purification of Fumonisins using Fast Centrifugal Partition Chromatography (FCPC).” contribution to the Mykotoxinworkshop, Utrecht
Scientific Talks
- Anderski, Juliane; Mahlert, Laura : “Interactions of nanoparticles with mucus - the first barrier before reaching intestinal cells”. Bad Herrenalber Transporter- und Barrieretage, Bad Herrenalb, Deutschland, .
- Raudszus, Bastian; Mulac, Dennis; Langer, Klaus : “Apo E-modification of PLA-nanoparticles enhances cellular uptake into brain endothelium”. 10th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Glasgow, Vereinigtes Königreich, .
Teaching
Courses:
"Pharmazeutische Technologie einschließlich Medizinprodukte" :
- "Feste Arzneiformen"
- "Sterile Arzneiformen"
- "Moderne Arzneiformen"